NOL11

Across TCGA pan-cancer cohorts, NOL11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NOL11 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NOL11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOL11 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where NOL11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.566	0.898	<.001	106	view →
LSCC	DFS	Tertile	II,III,IV	0.896	0.491	.006	20	view →
LUAD	DFS	Median	III,IV	0.928	0.553	.011	12	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
UCEC	DFS	Quartile	III,IV	1.000	0.300	.020	4	view →
GBM	OS	Quartile	All	0.619	0.274	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NOL11–CCRCC (DFS)

Open the CCRCC breakdown →